Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan province & Education Ministry of P.R. China, Zhengzhou, China.
Henan Key Laboratory of Chinese Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou, China.
Acupunct Med. 2022 Aug;40(4):389-400. doi: 10.1177/09645284221078873. Epub 2022 Feb 25.
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. Pulmonary vascular remodeling is the main pathological feature of COPD. Vascular endothelial growth factor (VEGF), the key regulator of angiogenesis, mediates activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, which regulates the proliferation and migration of vascular endothelial cells and plays important roles in pulmonary angiogenesis and remodeling in COPD. Here, the efficacy of electroacupuncture (EA) with respect to regulation of microvascular remodeling induced by VEGF/PI3K/Akt was evaluated in a rat model of COPD.
Rats were randomly assigned to blank, COPD model, EA and sham acupuncture (SA) groups. Rats in the EA group received EA at GV14, BL13 and BL23 three times per week, while those in the SA group, as a control, received shallow and minimal electrostimulation at sites 5-10 mm away from the traditional acupuncture point locations. After 2, 4 and 8 weeks of treatment, the optimal treatment duration was determined according to the results of lung function, lung pathology and inflammatory factor levels. Then, microvessel density, protein levels and mRNA expression of selected VEGF/PI3K/Akt pathway intermediates were determined by immunofluorescence, immunohistochemistry and Western blot analysis, and mRNA qRT-PCR, respectively.
EA improved lung function and lung tissue histopathology, with the best effect after 8 weeks of treatment, as noted by reduced density of lung microvessels and expression of angiogenesis-related factors (VEGF and endothelin (ET)-1). EA-treated COPD rats exhibited reduced VEGF, VEGF receptor 2 (VEGFR2), ET-1 mRNA and VEGF, VEGFR2, phosphorylated (p)-VEGFR2, PI3K, Akt, p-Akt, mammalian target of rapamycin (mTOR), and p-mTOR at the protein level in comparison with untreated and SA-treated COPD model rats.
EA had beneficial effects on COPD in this animal model including reduced pulmonary vascular remodeling via mechanisms possibly related to the VEGF/PI3K/Akt pathway.
慢性阻塞性肺疾病(COPD)的特征是气流受限,且不完全可逆。肺血管重塑是 COPD 的主要病理特征。血管内皮生长因子(VEGF)是血管生成的关键调节因子,它介导磷酸肌醇 3-激酶(PI3K)/蛋白激酶 B(Akt)通路的激活,该通路调节血管内皮细胞的增殖和迁移,在 COPD 中的肺血管生成和重塑中发挥重要作用。在这里,我们评估了电针对 VEGF/PI3K/Akt 诱导的微血管重塑的调节作用,以此研究电针对 COPD 大鼠模型的疗效。
将大鼠随机分为空白组、COPD 模型组、电针(EA)组和假针刺(SA)组。EA 组每周接受 3 次电针治疗,穴位为 GV14、BL13 和 BL23;SA 组作为对照,在距离传统针刺穴位 5-10mm 处接受浅而弱的电刺激。根据肺功能、肺病理和炎症因子水平的结果,确定最佳治疗持续时间。然后,通过免疫荧光、免疫组化和 Western blot 分析,以及实时荧光定量聚合酶链反应(qRT-PCR),分别测定微血管密度、选定的 VEGF/PI3K/Akt 通路中间产物的蛋白水平和 mRNA 表达。
EA 改善了肺功能和肺组织病理学,8 周治疗后效果最佳,表现为肺微血管密度降低和血管生成相关因子(VEGF 和内皮素(ET)-1)表达减少。与未治疗和 SA 治疗的 COPD 模型大鼠相比,EA 治疗的 COPD 大鼠的 VEGF、VEGF 受体 2(VEGFR2)、ET-1 mRNA 和 VEGF、VEGFR2、磷酸化(p)-VEGFR2、PI3K、Akt、p-Akt、雷帕霉素靶蛋白(mTOR)和 p-mTOR 蛋白水平均降低。
在该动物模型中,EA 对 COPD 具有有益的影响,包括通过可能与 VEGF/PI3K/Akt 通路相关的机制减少肺血管重塑。